Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
about
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.Treating ALK-positive non-small cell lung cancer.
P2860
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@ast
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@en
type
label
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@ast
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@en
prefLabel
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@ast
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@en
P2093
P2860
P1433
P1476
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
@en
P2093
Chang-Long Chen
De-Sheng Weng
Jian-Chuan Xia
Xiao-Fei Zhang
Zi-Qi Zhou
P2860
P2888
P356
10.1186/S12885-017-3405-3
P407
P577
2017-06-12T00:00:00Z
P6179
1085983006